

Andrew B Nixon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9082372/publications.pdf>

Version: 2024-02-01

158
papers

5,640
citations

159585

30
h-index

85541

71
g-index

161
all docs

161
docs citations

161
times ranked

9505
citing authors

#	ARTICLE	IF	CITATIONS
1	HDAC6 is a microtubule-associated deacetylase. <i>Nature</i> , 2002, 417, 455-458.	27.8	2,301
2	The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1115-1124.	4.2	271
3	Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression. <i>Hypertension</i> , 2009, 54, 652-658.	2.7	242
4	A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 2570-2586.	8.2	134
5	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 4268-4279.	7.0	126
6	Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?. , 2019, 7, 325.		111
7	Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1798-1808.	4.1	99
8	Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance). <i>Clinical Cancer Research</i> , 2013, 19, 6957-6966.	7.0	95
9	Type III TGF- β 2 receptor downregulation generates an immunotolerant tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2013, 123, 3925-3940.	8.2	94
10	Phosphorylation and Nuclear Translocation of a Regulator of G Protein Signaling (RGS10). <i>Journal of Biological Chemistry</i> , 2001, 276, 32828-32834.	3.4	90
11	5-Lipoxygenase Products Modulate the Activity of the 85-kDa Phospholipase A2 in Human Neutrophils. <i>Journal of Biological Chemistry</i> , 1995, 270, 26543-26549.	3.4	69
12	5-Oxo-eicosanoids and Hematopoietic Cytokines Cooperate in Stimulating Neutrophil Function and the Mitogen-activated Protein Kinase Pathway. <i>Journal of Biological Chemistry</i> , 1996, 271, 17821-17828.	3.4	68
13	Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance). <i>Clinical Cancer Research</i> , 2015, 21, 1078-1086.	7.0	67
14	TGF- β 2-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. <i>Carcinogenesis</i> , 2016, 37, 1041-1051.	2.8	67
15	Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. <i>Cancer Medicine</i> , 2013, 2, 234-242.	2.8	64
16	The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival. <i>Neuro-Oncology</i> , 2017, 19, 1217-1227.	1.2	53
17	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040.	5.9	48
18	A leave-one-out cross-validation SAS macro for the identification of markers associated with survival. <i>Computers in Biology and Medicine</i> , 2015, 57, 123-129.	7.0	45

#	ARTICLE	IF	CITATIONS
19	A Role for Gz in Pancreatic Islet Î²-Cell Biology. <i>Journal of Biological Chemistry</i> , 2005, 280, 31708-31713.	3.4	44
20	Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 251-258.	2.3	43
21	Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).. <i>Journal of Clinical Oncology</i> , 2019, 37, e15169-e15169.	1.6	43
22	Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-Î² signaling. <i>Oncogene</i> , 2014, 33, 3970-3979.	5.9	42
23	Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase IIIa clinical trial. <i>Annals of Oncology</i> , 2016, 27, 1579-1585.	1.2	41
24	Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. <i>Investigational New Drugs</i> , 2014, 32, 851-859.	2.6	40
25	Ectodomain shedding of TÎ²RIII is required for TÎ²RIII-mediated suppression of TGF-Î² signaling and breast cancer migration and invasion. <i>Molecular Biology of the Cell</i> , 2014, 25, 2320-2332.	2.1	39
26	A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas. <i>Oncologist</i> , 2013, 18, 271-272.	3.7	38
27	Acetyl-CoA:1-O-Alkyl-2-lyso-sn-glycero-3-phosphocholine Acetyltransferase Is Directly Activated by p38 Kinase. <i>Journal of Biological Chemistry</i> , 1999, 274, 5469-5473.	3.4	35
28	Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. <i>Blood</i> , 2019, 133, 1762-1765.	1.4	35
29	The Interaction of RGSZ1 with SCG10 Attenuates the Ability of SCG10 to Promote Microtubule Disassembly. <i>Journal of Biological Chemistry</i> , 2002, 277, 18127-18133.	3.4	34
30	Bevacizumab biosimilars: scientific justification for extrapolation of indications. <i>Future Oncology</i> , 2018, 14, 2507-2520.	2.4	32
31	Regulation of platelet-activating factor synthesis in human neutrophils by MAP kinases. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2002, 1592, 175-184.	4.1	31
32	A phase I study of ABT 510 plus bevacizumab in advanced solid tumors. <i>Cancer Medicine</i> , 2013, 2, 316-324.	2.8	31
33	Phase II study of Dovitinib in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 359-368.	2.9	29
34	Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. <i>Clinical Cancer Research</i> , 2020, 26, 1288-1296.	7.0	29
35	Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4005-4005.	1.6	29
36	Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3831-3842.	7.0	28

#	ARTICLE	IF	CITATIONS
37	Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. <i>Journal of Clinical Investigation</i> , 2014, 124, 3016-3031.	8.2	28
38	Modulation of circulating protein biomarkers following TRC 105 (anti-Endoglin antibody) treatment in patients with advanced cancer. <i>Cancer Medicine</i> , 2014, 3, 580-591.	2.8	27
39	The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 349-358.	1.4	25
40	A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 241-250.	1.9	25
41	Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4520-4520.	1.6	25
42	An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 202-210.	3.7	24
43	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1713.	7.1	24
44	A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. <i>Cancer</i> , 2020, 126, 3464-3470.	4.1	24
45	Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC). <i>J Clin Oncol</i> . 2021;39(14):1974-1984. doi:10.1200/JCO.2020.39.14.1974	10.784	314
46	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	6.3	24
47	The Balance of Cell Surface and Soluble Type III TGF- β 2 Receptor Regulates BMP Signaling in Normal and Cancerous Mammary Epithelial Cells. <i>Neoplasia</i> , 2014, 16, 489-500.	5.3	22
48	Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1048-1056.	4.1	22
49	Endoglin Targeting: Lessons Learned and Questions That Remain. <i>International Journal of Molecular Sciences</i> , 2021, 22, 147.	4.1	22
50	A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. <i>Anticancer Research</i> , 2011, 31, 255-61.	1.1	22
51	Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). <i>Cancer Medicine</i> , 2016, 5, 2249-2260.	2.8	19
52	A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. <i>Oncologist</i> , 2018, 23, 782-790.	3.7	19
53	Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 564.	7.1	19
54	Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. <i>Gynecologic Oncology</i> , 2019, 153, 555-561.	1.4	19

#	ARTICLE	IF	CITATIONS
55	Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014, 32, 330-339.	2.6	18
56	Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 510-518.	1.6	18
57	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2146-2154.	4.1	18
58	Role of TGF- β 2 receptor III localization in polarity and breast cancer progression. <i>Molecular Biology of the Cell</i> , 2014, 25, 2291-2304.	2.1	17
59	Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2248-2256.	4.1	17
60	RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer. <i>JCI Insight</i> , 2019, 4, .	5.0	17
61	Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines. <i>Gynecologic Oncology Research and Practice</i> , 2014, 1, 2.	3.6	16
62	Dual inhibition of β 1 integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. <i>Anti-Cancer Drugs</i> , 2013, 24, 237-250.	1.4	15
63	Dynamic Changes in Circulating Tumor DNA During Chemoradiation for Locally Advanced Lung Cancer. <i>Advances in Radiation Oncology</i> , 2019, 4, 748-752.	1.2	15
64	EGFR-Dependent IL8 Production by Airway Epithelial Cells After Exposure to the Food Flavoring Chemical 2,3-Butanedione. <i>Toxicological Sciences</i> , 2019, 169, 534-542.	3.1	15
65	Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma. <i>Radiology</i> , 2017, 285, 311-318.	7.3	14
66	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non- α -Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3317-3328.	7.0	14
67	Comparison of alkylacylglycerol vs. diacylglycerol as activators of mitogen-activated protein kinase and cytosolic phospholipase A2 in human neutrophil priming. <i>Lipids and Lipid Metabolism</i> , 1997, 1347, 219-230.	2.6	13
68	A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). <i>EBioMedicine</i> , 2015, 2, 1814-1820.	6.1	13
69	A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 909-917.	2.3	13
70	Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 465-e917.	3.7	13
71	Differential activation of human neutrophil cytosolic phospholipase A2 and secretory phospholipase A2 during priming by 1,2-diacyl- and 1-O-alkyl-2-acylglycerols. <i>Lipids and Lipid Metabolism</i> , 1998, 1394, 224-234.	2.6	11
72	Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 322-326.	2.0	11

#	ARTICLE	IF	CITATIONS
73	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2779-2788.	7.0	11
74	Genetic variation determines VEGF-A plasma levels in cancer patients. <i>Scientific Reports</i> , 2018, 8, 16332.	3.3	10
75	A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 1032.	2.6	9
76	Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3597-3597.	1.6	9
77	A facile synthesis of 1-O-alkyl-2-(R)-hydroxypropane-3-phosphonocholine (lyso-phosphono-platelet) Tj ETQq1 1 0.784314 rgBT /Overlo	3.2	8
78	Evaluation of phospholipase C and D activity in stimulated human neutrophils using a phosphono analog of choline phosphoglyceride. <i>Lipids and Lipid Metabolism</i> , 1993, 1169, 25-29.	2.6	8
79	Comparison of acceptor and donor substrates in the CoA-independent transacylate reaction in human neutrophils. <i>Lipids and Lipid Metabolism</i> , 1996, 1300, 187-196.	2.6	8
80	Analysis of the Regulation of Microtubule Dynamics by Interaction of RGSZ1 (RGS20) with the Neuronal Stathmin, SCG10. <i>Methods in Enzymology</i> , 2004, 390, 53-64.	1.0	8
81	Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance). <i>Angiogenesis</i> , 2022, 25, 47-55.	7.2	8
82	Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformations. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 372.	2.7	8
83	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN± A± Bevacizumab: Results from CALGB 90206 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2771-2778.	7.0	8
84	A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 343-352.	2.3	7
85	Microtransplantation in older patients with <scp>AML</scp>: A pilot study of safety, efficacy and immunologic effects. <i>American Journal of Hematology</i> , 2020, 95, 662-671.	4.1	7
86	Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). <i>Gynecologic Oncology</i> , 2021, 161, 382-388.	1.4	7
87	Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancers. <i>Communications Biology</i> , 2022, 5, .	4.4	7
88	Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data. <i>Cancer Informatics</i> , 2014, 13s4, CIN.S13634.	1.9	6
89	Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 218-225.	2.5	6
90	Developing elite <i>Neurospora crassa</i> strains for cellulosic ethanol production using fungal breeding. <i>Journal of Industrial Microbiology and Biotechnology</i> , 2017, 44, 1137-1144.	3.0	6

#	ARTICLE	IF	CITATIONS
91	A phase I study of gemcitabine+dasatinib (gd) or gemcitabine+dasatinib+cetuximab (GDC) in refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1025-1035.	2.3	6
92	Proteomic Analysis of Infants Undergoing Cardiopulmonary Bypass Using Contemporary Ontological Tools. <i>Journal of Surgical Research</i> , 2020, 246, 83-92.	1.6	6
93	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa074.	2.9	6
94	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). <i>Oncologist</i> , 2021, 26, 560-e1103.	3.7	6
95	Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4082-4082.	1.6	6
96	Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9065-9065.	1.6	6
97	Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. <i>Clinical Cancer Research</i> , 2015, 21, 3442-3452.	7.0	5
98	Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin+paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5521-5521.	1.6	5
99	Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1077-1077.	1.6	5
100	Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 700-709.	2.6	4
101	Constancy checks of well-type ionization chambers with external-beam radiation units. <i>Journal of Applied Clinical Medical Physics</i> , 2015, 16, 508-514.	1.9	4
102	An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). <i>Pharmacogenetics and Genomics</i> , 2019, 29, 123-131.	1.5	4
103	Pleural effusions associated with squamous cell lung carcinoma have a low diagnostic yield and a poor prognosis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2500-2508.	2.8	4
104	AdoRN Trial: Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly-diagnosed advanced-stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 162, S61.	1.4	4
105	Phase II trial of dovitinib in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2050-2050.	1.6	4
106	Differential expression of immune related genes in high-grade ovarian serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 662-668.	1.4	3
107	A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. <i>PLoS ONE</i> , 2021, 16, e0252995.	2.5	3
108	Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study. <i>Current Medical Research and Opinion</i> , 2021, 37, 1769-1778.	1.9	3

#	ARTICLE	IF	CITATIONS
109	Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487).. Journal of Clinical Oncology, 2013, 31, 4042-4042.	1.6	3
110	A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.. Journal of Clinical Oncology, 2018, 36, 3555-3555.	1.6	3
111	Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).. Journal of Clinical Oncology, 2019, 37, 4083-4083.	1.6	3
112	Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.. Journal of Clinical Oncology, 2020, 38, TPS3154-TPS3154.	1.6	3
113	A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. Anticancer Research, 2010, 30, 1251-6.	1.1	3
114	fastJT: An R package for robust and efficient feature selection for machine learning and genome-wide association studies. BMC Bioinformatics, 2019, 20, 333.	2.6	2
115	Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).. Journal of Clinical Oncology, 2021, 39, 325-325.	1.6	2
116	Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.. Journal of Clinical Oncology, 2019, 37, 3552-3552.	1.6	2
117	A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with <i>MET</i> amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.. Journal of Clinical Oncology, 2020, 38, TPS270-TPS270.	1.6	2
118	Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. Oncologist, 2022, 27, 621-e617.	3.7	2
119	Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers. Cancer Chemotherapy and Pharmacology, 2022, 89, 413-422.	2.3	2
120	MP44-01 A PROGNOSTIC MODEL FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CARCINOMA: RESULTS FROM CALGB 90206 (ALLIANCE). Journal of Urology, 2015, 193, .	0.4	1
121	Cabozantinib in ovarian clear cell cancers: UnMET expectations. Gynecologic Oncology, 2018, 150, 1-2.	1.4	1
122	Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. Prostate, 2019, 79, 1752-1761.	2.3	1
123	Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.. Journal of Clinical Oncology, 2021, 39, 361-361.	1.6	1
124	The Targeting of Leukocytes by 5-Oxo-Eicosanoids. , 1996, , 149-155.		1
125	Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.. Journal of Clinical Oncology, 2014, 32, 4532-4532.	1.6	1
126	HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev).. Journal of Clinical Oncology, 2015, 33, 4543-4543.	1.6	1

#	ARTICLE	IF	CITATIONS
127	HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC).. Journal of Clinical Oncology, 2015, 33, 3583-3583.	1.6	1
128	Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side.. Journal of Clinical Oncology, 2017, 35, 3528-3528.	1.6	1
129	Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).. Journal of Clinical Oncology, 2017, 35, 4522-4522.	1.6	1
130	Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.. Journal of Clinical Oncology, 2017, 35, 11546-11546.	1.6	1
131	Correlation of imaging and plasma-based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC): A GOG 218 ancillary data analysis.. Journal of Clinical Oncology, 2018, 36, 5507-5507.	1.6	1
132	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, TPS4150-TPS4150.	1.6	1
133	Plasma levels of VEGF and VCAM as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitors. British Journal of Clinical Pharmacology, 2022, , .	2.4	1
134	A precision medicine approach to stress testing using metabolomics and microribonucleic acids. Personalized Medicine, 2022, 19, 287-297.	1.5	1
135	Variation in Microenvironmental Effects and Drug Delivery between Different Classes of Antiangiogenic Drugs. International Journal of Radiation Oncology Biology Physics, 2010, 78, S164-S165.	0.8	0
136	A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients. Annals of Oncology, 2018, 29, viii661-viii662.	1.2	0
137	Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance).. Journal of Clinical Oncology, 2021, 39, 154-154.	1.6	0
138	Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.. Journal of Clinical Oncology, 2021, 39, 3568-3568.	1.6	0
139	Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance).. Journal of Clinical Oncology, 2021, 39, 343-343.	1.6	0
140	Modulation of angiogenic biomarkers in patients receiving high-dose TRC105.. Journal of Clinical Oncology, 2012, 30, e21038-e21038.	1.6	0
141	Modulation of pharmacodynamic (PD) biomarkers in dermal biopsies from patients treated on a phase I study of bevacizumab (Bev) in combination with everolimus (Ev) and erlotinib (Erl) for advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, e13589-e13589.	1.6	0
142	Abstract 5041: The type III TGF-beta receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.. , 2013, , .		0
143	Correlation of Src activation with response to dasatinib, capecitabine, oxaliplatin, and bevacizumab in advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 11036-11036.	1.6	0
144	Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance).. Journal of Clinical Oncology, 2013, 31, 11011-11011.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).. Journal of Clinical Oncology, 2014, 32, 448-448.	1.6	0
146	Activation of 85 kDa PLA2 by Eicosanoids in Human Neutrophils and Eosinophils. Advances in Experimental Medicine and Biology, 1996, 416, 327-331.	1.6	0
147	Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).. Journal of Clinical Oncology, 2014, 32, 11022-11022.	1.6	0
148	Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.. Journal of Clinical Oncology, 2014, 32, 11020-11020.	1.6	0
149	Abstract 2674: Stroma biology identifies heparins as differentiating agents in neuroblastoma. , 2014, , .		0
150	Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance).. Journal of Clinical Oncology, 2015, 33, 306-306.	1.6	0
151	Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, 3570-3570.	1.6	0
152	Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.. Journal of Clinical Oncology, 2019, 37, 587-587.	1.6	0
153	On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2019, 37, 588-588.	1.6	0
154	Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2019, 37, 3035-3035.	1.6	0
155	Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with ipilimumab/nivolumab (I+N).. Journal of Clinical Oncology, 2020, 38, 731-731.	1.6	0
156	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.. Journal of Clinical Oncology, 2022, 40, 284-284.	1.6	0
157	Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia. PLoS ONE, 2022, 17, e0268963.	2.5	0
158	Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2022, 40, 3553-3553.	1.6	0